Towards evidence-based response criteria for cancer immunotherapy
Elena Garralda, Scott A. Laurie, Lesley Seymour, Elisabeth G.E. de Vries
Abstract
Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.
Topics & Concepts
ImmunotherapyGuidelineMedicineResponse Evaluation Criteria in Solid TumorsCancer immunotherapyCancerOncologyMedical physicsClinical trialInternal medicinePathologyPhases of clinical researchCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesLung Cancer Research Studies